| pubmed-article:19654949 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0441771 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C2825926 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:19654949 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:19654949 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19654949 | pubmed:dateCreated | 2009-8-5 | lld:pubmed |
| pubmed-article:19654949 | pubmed:abstractText | High-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was applied to improve the prognosis of patients with high-risk stage 3 neuroblastoma. From January 1997 to December 2006, 28 patients were newly diagnosed as stage 3 neuroblastoma. Nine of 11 patients with N-myc amplification and 5 of 17 patients without N-myc amplification (poor response in 2 patients, persistent residual tumor in 2 and relapse in 1) underwent single or tandem HDCT/ASCR. Patients without high-risk features received conventional treatment modalities only. While 8 of 9 patients underwent single HDCT/ASCR and the remaining one patient underwent tandem HDCT/ASCR during the early study period, all 5 patients underwent tandem HDCT/ASCR during the late period. Toxicities associated with HDCT/ASCR were tolerable and there was no treatment-related mortality. While the tumor relapsed in two of eight patients in single HDCT/ASCR group, all six patients in tandem HDCT/ASCR group remained relapse free. The 5-yr event-free survival (EFS) from diagnosis, in patients with N-myc amplification, was 71.6+/-14.0%. In addition, 12 of 14 patients who underwent HDCT/ASCR remained event free resulting in an 85.1+/-9.7% 5-yr EFS after the first HDCT/ASCR. The present study demonstrates that HDCT/ASCR may improve the survival of patients with high-risk stage 3 neuroblastoma. | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19654949 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19654949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19654949 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19654949 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19654949 | pubmed:issn | 1598-6357 | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:KimJhingookJ | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:SuhYeon LimYL | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:KimDae WonDW | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:SungKi... | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:YooKeon HeeKH | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:ChoEun JooEJ | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:KooHong HoeHH | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:LeeSuk KooSK | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:LimDo... | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:KimJu YounJY | lld:pubmed |
| pubmed-article:19654949 | pubmed:author | pubmed-author:SuhJung MinJM | lld:pubmed |
| pubmed-article:19654949 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19654949 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:19654949 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19654949 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19654949 | pubmed:pagination | 660-7 | lld:pubmed |
| pubmed-article:19654949 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:meshHeading | pubmed-meshheading:19654949... | lld:pubmed |
| pubmed-article:19654949 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19654949 | pubmed:articleTitle | High-dose chemotherapy and autologous stem cell rescue in patients with high-risk stage 3 neuroblastoma: 10-year experience at a single center. | lld:pubmed |
| pubmed-article:19654949 | pubmed:affiliation | Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. | lld:pubmed |
| pubmed-article:19654949 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19654949 | pubmed:publicationType | Case Reports | lld:pubmed |
